Best Immunotherapy Companies in Israel
The 32 best Immunotherapy companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NeoTX.
- The Business Research Company
- ResearchAndMarkets.com
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Israel
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Biolojic Design Developer of human antibody-based therapeutics for cancer and auto immune diseases | — | — | Funding Raised | — | 52 | WordPressApple iCloud MailMicrosoft 365+25 | 38 patents Bispecific antibody engineering for targeted cancer and immune therapies | — |
| 2 | Edity Developer of a drug delivery platform based on gene-editing technology | — | — | Funding Raised | Michal Golan Mashiach Founder & CEO | 20 | WordPressMySQLPHP+17 | — | — |
| 3 | Fusimab Bi-specific antibodies for cancer | — | — | Deadpooled | Iris Alroy ex-CEO | — | — | — | — |
| 4 | Gammacan International Developer of cancer treating technology in Israel. The company's technology focuses on the development of… | — | — | Private | — | 8 | — | 10 patents Therapeutic polyclonal anti‑VEGF antibodies and vitiligo‑derived immunoglobulins for melanoma treatment | — |
| 5 | Gilboa Developer of immunotherapeutics for the treatment of cancer | — | — | Unfunded | Yaron Carmi Co-Founder | — | — | — | — |
| 6 | Iluten Receptor targeting MAb for IBD & multiple sclerosis | — | — | Deadpooled | Amotz Nechushtan Founder & CEO | — | — | — | — |
| 7 | ImmunoCord Graft engineering of cord blood as enhanced adoptive immunotherapy against solid tumors | — | — | Deadpooled | Amnon Pelz Founder & CEO | — | — | — | — |
| 8 | Nectintx Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system. | — | — | Private | Ofer Mandelboim Co-Founder | 11 | WordPressPleskMySQL+22 | — | — |
Top 12 Immunotherapy companies in Israel
#1
Series D · Jerusalem, Jerusalem District · founded 2005 · 32 employees$58.5Mraised▾
Developer of immune therapeutics to treat cancer. The company's product candidates include DSP107 SIRPα-41BBL, DSP105 PD1-41BBL, and TSPs TIGIT/LILRB/SIGLEC used for the treatment of solid tumour. The company has developed its proprietary MIRP (Multifunctional Immune Recruitment Protein) technology for the discovery of immuno-recruitment drugs. It is used to target the immune checkpoints for unmasking cancer camouflage mechanisms.
- Nov 2022Series D—
- May 2021Series C$46.5M
- Jan 2019Grant (prize money)$151.5K
- Dec 2015Series B$12M
#2
Series C · Misgav, Northern District · founded 2016 · 34 employees$32Mraised▾
Developer of immunotherapies for oncology and autoimmune diseases. The lead candidate BND 22 is an immune checkpoint inhibitor for solid tumors, BION-206 is a VHH antibody, enhances phagocytosis, and BND-35 is an antibody targeting ILT3 receptor for the treatment of solid tumors. The INspire technology is a platform for the internalization of antibodies into cells, addressing “undruggable” intracellular targets.
- Nov 2021Series C$15M
- Jan 2019Series B$17M
#3
Public · Holon, Tel Aviv District · founded 1993 · 20 employees$35.4Mraised▾
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The company predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program.
#4
Series C · Rehovot, Central District · founded 2016 · 33 employees$100.9Mraised▾
NeoTX is focussed on developing immunotherapy-based late-stage cancer drugs. Its lead candidate Anyara (protein drug) is a TTS (Tumor Targeting Superantigen) which claims to increase the ability of the immune system to recognize the tumor. The candidate has finished clinical phase 1 trials for lung cancer, renal cell cancer and pancreatic cancer where it was studied as a single agent as well as in combination with docetaxel (chemotherapy). In October 2016, NeoTX entered into a partnership with Active Biotech for the development and commercialization of Anyra. As of December 2016, it is planning for a trial in combination with drugs that inhibit checkpoint dampening of the immune system.
- Feb 2020Series C$45M
- Oct 2019Series B$37.9M
- Aug 2019Series A$9.2M
- Oct 2016Series A$8.8M
#5
Public · Ness Ziona, Center District · founded 2003$49.9Mraised▾
Developer of a vaccine against influenza virus. Its lead candidate M-001, a nanosized antibody vaccine to protect against seasonal and pandemic influenza. Its technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
- Apr 2019Conventional Debt$26.9M
- Oct 2018Conventional Debt$9.2M
- Aug 2018Conventional Debt$6.8M
- Jun 2018Conventional Debt$7M
#6
Acqui-Hired · Rehovot, Central District · founded 2005$53.8Mraised▾
SciVac Therapeutics (formerly SciGen IL) was a clinical stage company focussed on developing a vaccine for viral infections. It had developed hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus which provides rapid onset of protection, high levels of anti-HBV antibodies, and can be administered at lower doses than competing HBV vaccines. The vaccine was approved in Israel and in 14 other countries . In May 2016, SciVac Therapeutics merged with VBI Vaccines and changed its name to VBI Vaccines. It's Israel unit is currently serving as contract development unit.
- Jul 2015Post IPO—
- Oct 2014Post IPO$4.4M
- Aug 2010Post IPO$274.7K
#7
Acquired · Petah Tikva, Central District · founded 2008 · 11 employees$26Mraised▾
MacroCure develops and commercialized T-cell therapies for wound care. Its proprietary technology CureXcell® employs activated white blood cells obtained from healthy donor blood to promote advanced wound healing. CureXcell is currently in two pivotal Phase III trials for lower extremity chronic ulcers and chronic venous leg ulcers.
- Apr 2011Series B$13M
- Sep 2009Series A$8M
- Mar 2009Series A$5M
#8
Public · Tel Aviv, Tel Aviv · founded 2011 · 37 employees$15Mraised▾
ChemomAb is focussed on the development of proprietary targeting monoclonal antibodies for the treatment of immune-mediated and fibrotic disorders. Its technology is based on the chemokine pathway it has identified which mediates inflammation and fibrosis. Its lead candidate CM-101 was granted orphan drug designation by both EMA & FDA to treat idiopathic pulmonary fibrosis & systemic sclerosis. The candidate has completed pre-clinical trials and is heading towards clinical trials during 2017.
- Dec 2017Series B$10M
- Series A$5M
#9
Series A · Rehovot, Central District · founded 2009 · 13 employees$4.5Mraised▾
Efranat develops cancer immunotherapies based on glycoprotein mimics. It targets the Vitamin D binding protein that is known to activate macrophage activity and whose activity is suppressed in cancer patients. Its lead candidate mimics this glycoprotein and acts as an immunomodulator, triggering an immune response against tumor cells. It is currently in phase I trials for solid tumors.
- Nov 2014Series A$4.5M
- Nov 2011Seed—
#10
Deadpooled · Jerusalem, Jerusalem District · founded 2005$4Mraised▾
ProtAb, a subsidiary of Hadasit BioHoldings (HBL) is focussed on developing immunotherapeutic drugs for autoimmune inflammatory diseases. Its lead candidate is an anti-peptide 6 monoclonal antibody (aP6mab) which is currently in preclinical trials for rheumatoid arthritis and type-1 diabetes. It also has a strong IP estate, whereby it has received from Hadasit, an exclusive license to certain patents and patent applications relating to HSP65/HSP60 peptides and antibodies against these peptides for the treatment of autoimmune diseases.
- Apr 2010Series A$4M
#11
Series A · Rehovot, Central District · founded 2015$2.5Mraised▾
Predictive Therapeutics is a clinical stage oncology company focussed on developing immunotherapies. Its approach is based on acquiring undervalued late stage assets for the clinical development. It is currently building a late-stage pipeline of differentiated cancer therapies with the lead candidate PT-101, which coats tumor cells with molecules which direct the patient’s immune system against the tumor and claims to through the phase 3 clinical development with acceptable safety.
- Oct 2015Series A$2.5M
#12
Series A · Jerusalem, Jerusalem District · founded 2004 · 18 employees$1.5Mraised▾
Immunovative Therapies is a clinical stage biopharmaceutical company specializing in the translation of proven immune mechanisms into immunotherapy products and protocols for treatment of cancer and infectious diseases. Its patented “Mirror Effect” technology provides an immunological platform for the development of drugs that elicit the same powerful antitumor and anti-HIV effects of bone marrow/stem cell transplant procedures while eliminating the side effects of the procedure and the need for a tissue-matched donor. It has two products in clinical development: AlloStim®, a bioengineered living cell allograft; and Chaperone-Rich Cell Lysate (CRCL), a patient-specific heat shock protein vaccine. AlloStim® cells are activated allogeneic Th1 memory T-cells containing cytolytic granules. CRCL is a source of patient-specific tumor antigens. AlloVax® is a therapeutic anti-cancer vaccine consisting of CRCL as the source of tumor antigen and AlloStim® as an adjuvant. The intradermal injection of AlloVax® elicits tumor-specific Th1 immunity.
- Jan 2008Series A$1.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in Israel
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 268 Israel-affiliated papers.
- Hadassah Medical Center43
- Tel Aviv University41
- Hebrew University of Jerusalem37
- Technion – Israel Institute of Technology31
- Ben-Gurion University of the Negev30
- Immune system3→31
- Cancer immunotherapy1→11
- Cancer1→10
- Antigen2→7
- Cancer research2→5
- Immune system5→36
- Pembrolizumab1→16
- Internal medicine2→16
- Oncology2→15
- Chimeric antigen receptor1→10
- Immune system8
- Disease7
- Internal medicine5
- Cancer4
- Autoimmune disease4
Where immunology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.